The prices for some GLP-1s have dropped significantly in recent years for individuals covered by Medicare and commercial insurance, according to a new report from HHS.
In 2024, the U.S. list prices for a one-month supply for most GLP-1s are stable or increasing, but after payer negotiations and rebates, net prices for many GLP-1s have decreased since 2022. Net prices for GLP-1s are between 24% and 73% lower than list prices, indicating that most insurers are paying less than the manufacturer's list price.
"In the net prices, we see evidence of the impact of competition as new drugs in the class enter the market," HHS wrote. "While list prices are consistently stable or increasing, for many of these drugs, including Ozempic, Rybelsus, Saxenda, and Victoza, net prices fell."
2024 net price for weight loss drugs:
Zepbound: $809
Saxenda: $703
Wegovy: $649
Rybelsus: $296
Mounjaro: $291
Ozempic: $290
Victoza: $282